Osmol Therapeutics
Business Services · Connecticut, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
33 Whitney Ave Fl 3, New Haven, Connecti...Phone Number
(203) 606-5600Website
www.osmoltherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Osmol Therapeutics
Osmol Therapeutics is a privately held biopharma company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathyExplore more
Osmol Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Osmol Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Osmol Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Osmol Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Osmol Therapeutics
Check out if Osmol Therapeutics is spiking on competitors!
Click to see if Osmol Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Osmol Therapeutics launches new products
Earning: See what the market has to say on Osmol Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Osmol Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Osmol Therapeutics
Find more new buyers
Compare Similar Companies to Osmol Therapeutics
Compare insights from companies similar to Osmol Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Osmol Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Osmol Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Osmol Therapeutics.
Osmol Therapeutics Tech Stack
A closer look at the technologies used by Osmol Therapeutics
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Lateral Move
Executive Move
New Hire
Executive Move
New Hire
Executive Move
Osmol Therapeutics News & Media
Osmol Therapeutics Appoints Christopher S. Eklund to its Board of Directors
NEW HAVEN, Conn., May 15, 2024 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced the appointment of Christopher S. Eklund, Managing Director and Partner at venture capital investment firm, J.W. Childs Associates, to its Board of Directors.FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 Clinical Trial of OSM-0205 for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN) May Proceed
NEW HAVEN, Conn.--(BUSINESS WIRE)--Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN), today announced that the U.S. Food and Drug Administration (FDA) notified the company that the first-in-human clinical trial of OSM-0205 in healthy subjects for the prevention of CIPN may proceed. Osmol filed the Investigational New Drug application (IND) with the FDA for OSM-0205 in August 2023. MicrotuOsmol Therapeutics Provides Corporate Update at BIOTECH SHOWCASE 2023
NEW HAVEN, Conn.--(BUSINESS WIRE)--Osmol Therapeutics, today announced that it is presenting at BIOTECH SHOWCASE 2023, a leading investor conference focused on driving advances in therapeutic development taking place in San Francisco from January 9-11, 2023. Presentation details: Bob Linke, Chief Executive Officer, Osmol Therapeutics January 9, 2023, at 9:00 a.m. PST Hilton Union Square, 333 O’Farrell Street, Franciscan B (Ballroom Level), San Francisco CA Registered attendees can view Osmol’sOsmol Therapeutics Announces Appointment of Teresa Bitetti, President, Global Oncology Business Unit at Takeda Pharmaceuticals, to the Board of Directors
NEW HAVEN, Conn.--(BUSINESS WIRE)--Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN), today announced that Teresa Bitetti, President of the Global Oncology Business Unit at Takeda Pharmaceutical Company Ltd., has joined the Board of Directors of Osmol Therapeutics. CIPN affects approximately 80 percent of the estimated 360,000 patients who are treated with taxanes in the U.S. and European
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Osmol Therapeutics
Sign Up For FreeTo access detailed company insights
Osmol Therapeutics is a privately held biopharma company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy... Read More
